In 2008, Concortis Biosystems was established with the goal to better serve the scientific and pharmaceutical community with high quality antibody-drug conjugate (ADC) reagents and services. The intention was to develop next generation ADC technology.
In 2012, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) acquired Concortis Biosystems creating a top tier ADC company. The combination of G-MAB™ (fully human antibody library) with Concortis proprietary toxins, linkers, and conjugation methods would generate an industry-leading, 3rd generation ADC.
On October 19, 2015, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the partition of Concortis Biosystems into two separate companies, Levena Biopharma and Concortis Biotherapeutics.
Levena Biopharma will continue to offer the antibody community a broad range of ADC services from the initiation of an ADC project through cGMP manufacturing of ADCs to phase I/II clinical studiesby integrating current Concortis ADC service business. For detail information, please visit www.levenabiopharma.com.
Concortis Biotherapeutics was established to focus on developing next generation ADC to address the unmet medical need. Currently wehave approximately 20 ADC programs in preclinical stage, and in 2017, we plan to enroll patients in four clinical trials. Our mission is to be a leading antibody-drug conjugate (ADC) developer of next generation ADCs with focus on development of "first-in-class" and "best-in-class" antibody drug conjugates (ADCs).